Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer

Phase 2 Completed 15 enrolled Cancer Trials Ireland

NaSingle-groupOpen-labelTreatment

Summary

The trial is designed to establish whether adding a vitamin D analogue, Paricalcitol, to standard chemotherapy treatment, Gemcitabine and Nab-paclitaxel, can improve the outcomes for patients with advanced pancreatic cancer.

Timeline

Start: 2020-10-16
Primary completion: 2022-09-30
Completion: 2022-09-30

Outcome

Missed primary endpoint

paper The study did not meet its primary objective and discontinued following interim analysis. PMID 41535788 ↗

paper The prespecified efficacy threshold for 6-month progression free survival probability (≥ 70%) was not met. PMID 41535788 ↗

Publications

Easty D, McDermott R, Murphy AG, Grogan L, Morris PG, Breathnach OS, Egan K, Toomey S, Horgan A, Power D, Osman N, Parker I, Donachie V, Shevlin A, Barrett A, Nolan M, Marron J, Farr CJ, Hennessy BT. Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in advanced pancreatic cancer. BMC Cancer. 2026 Jan 15;26(1):255. doi: 10.1186/s12885-025-14512-2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Paricalcitol	Other / unclassified	12 ug	Oral
Background	Gemcitabine	Small molecule	1000 mg/m2	—
Background	Nab-paclitaxel	Small molecule	125 mg/m2	—